Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic Castration-Resistant Prostate Cancer

December 20th 2023

Treatment with 177Lu-PNT2002 resulted in a significant improvement in radiographic progression-free survival vs abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer whose disease had progressed on an androgen receptor pathway inhibitor.

Optimizing Care of Patients With Advanced Prostate Cancer: Introduction

December 19th 2023

Brief background on prostate cancer and overview of the program.

Lutetium Lu 177 Vipivotide Tetraxetan Addresses Unmet Need in Taxane-Naive mCRPC

December 18th 2023

Oliver Sartor, MD, discusses the significance of the data with lutetium Lu 177 vipivotide tetraxetan in the open-label, multicenter randomized study, highlights potential next steps with this approach, and expands on unique adverse effects to be aware of when treating patients with this drug.

TRT in Patients With Prostate Cancer on Active Surveillance: Are We Really Putting Gas on Fire?

December 18th 2023

Investigators hypothesized that testosterone replacement does not have a negative impact on the oncologic outcomes of treatment-naive patients with prostate cancer on surveillance and they performed a retrospective review of an institutional active surveillance prostate cancer database.

Revolutionizing Prostate Cancer Care: 2023’s Transformative Breakthroughs

December 18th 2023

Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.

Data from the DEAR Real-World Study and Strategies for Optimizing Outcomes

December 18th 2023

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.

Evolving Insights into Castration Resistance: Novel Biomarkers Predicting Disease Progression

December 15th 2023

Dr. Tanya Dorff and Dr. Rana McKay discuss the mechanisms driving castration resistance and how emerging epigenetic biomarkers may transform prognosis.

Evolving Paradigms in the Detection and Treatment of Prostate Cancer

December 15th 2023

Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.

Dr Freedland on the FDA Approval of Enzalutamide in nmCSPC

December 8th 2023

Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Novel Combination Regimens Are Expanding the Prostate Cancer Treatment Paradigm

December 1st 2023

Marijo Bilusic, MD, PhD, highlights key points presented at the meeting, including considerations with PARP inhibitor combinations for patients with mCRPC, how disease characteristics factor into treatment selection for patients with hormone-sensitive prostate cancer, and more.

Dr Wise on the Importance of Genetic Testing in mCRPC

November 30th 2023

David R. Wise, MD, PhD, discusses the importance of germline and somatic testing in patients with metastatic castration-resistant prostate cancer, and the need for improved testing practices in clinical practice.

FDA Approves Enzalutamide for nmCSPC With High-Risk Biochemical Recurrence

November 17th 2023

The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

Pembrolizumab Plus Enzalutamide/ADT Fails to Improve rPFS in mHSPC

November 15th 2023

The addition of pembrolizumab (Keytruda) to enzalutamide (Xtandi) and androgen deprivation therapy did not improve radiographic progression-free survival vs placebo plus enzalutamide and ADT in patients with metastatic hormone-sensitive prostate cancer, according to data from the phase 3 KEYNOTE-991 trial presented at the 2023 ESMO Congress.

State of the Science Summit - RCC/Prostate Cancer: Chaired by Manojkumar Bupathi, MD, MS

November 11th 2023

State of the Science Summit - RCC/Prostate Cancer: Chaired by Manojkumar Bupathi, MD, MS

Dr Scher on the Importance of Molecular Testing in Prostate Cancer

November 10th 2023

Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.

Reflecting on Advances Made in High-Risk, Low-Grade Prostate Cancer Management

November 10th 2023

Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.

BXCL701/Pembrolizumab Combo Prolongs OS in mCRPC of Adenocarcinoma Phenotype

November 8th 2023

Treatment with the oral innate immune activator BXCL701 combined with pembrolizumab demonstrated prolonged overall survival in patients with metastatic castration-resistant prostate cancer of adenocarcinoma phenotype.

STEAP1 Offers Potential Multifunctional Target in Prostate Cancer

November 8th 2023

Because STEAP1 is often overexpressed in prostate cancer, a disease that still largely lacks safe and effective treatment options, investigators are using it as the basis for developing novel therapies.

Dr Lowentritt on the Exploration of Active Surveillance in Prostate Cancer

November 6th 2023

Benjamin H. Lowentritt, MD, FACS, discusses the exploration of active surveillance in patients with prostate cancer.

Dr Morris on Active Surveillance in Low- and Intermediate-Risk Patients With Prostate Cancer

November 3rd 2023

David Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.